Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Kenichi Katsurada, Toshihiko Yada
Journal of Diabetes Investigation (2016) Vol. 7, Iss. S1, pp. 64-69
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

The role of short-chain fatty acids in microbiota–gut–brain communication
Boushra Dalile, Lukas Van Oudenhove, Bram Vervliet, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 8, pp. 461-478
Open Access | Times Cited: 2196
Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity
Katharina Timper, Jens C. Brüning
Disease Models & Mechanisms (2017) Vol. 10, Iss. 6, pp. 679-689
Open Access | Times Cited: 657
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
Kenneth J. O’Riordan, Michael Collins, Gerard M. Moloney, et al.
Molecular and Cellular Endocrinology (2022) Vol. 546, pp. 111572-111572
Open Access | Times Cited: 299
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands, Julian Ik‐Tsen Heng, Philip Newsholme, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 236
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 171
The gut microbiota–brain axis in neurological disorder
Hanif Ullah, Safia Arbab, Yali Tian, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 105
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 73
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 71
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
Melissa A. Burmeister, Jennifer Ayala, Hannah Smouse, et al.
Diabetes (2016) Vol. 66, Iss. 2, pp. 372-384
Open Access | Times Cited: 112
Diet in Parkinson's Disease: Critical Role for the Microbiome
Aeja Jackson, Christopher B. Forsyth, Maliha Shaikh, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 108
Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease
Jayasankar Kosaraju, R. M. Damian Holsinger, Lixia Guo, et al.
Molecular Neurobiology (2016) Vol. 54, Iss. 8, pp. 6074-6084
Closed Access | Times Cited: 102
Chenodeoxycholic Acid Ameliorates AlCl3-Induced Alzheimer’s Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats
Firas H. Bazzari, Dalaal M. Abdallah, Hanan S. El‐Abhar
Molecules (2019) Vol. 24, Iss. 10, pp. 1992-1992
Open Access | Times Cited: 86
Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway
Shuang Song, Ruoyi Guo, Arshad Mehmood, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 28, Iss. 3, pp. 422-434
Open Access | Times Cited: 66
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906
Arvid Jungnik, Jorge Arrubla, Leona Plum‐Mörschel, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1011-1023
Open Access | Times Cited: 46
POTENTIAL ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS IN SUBSTANCE USE DISORDER: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS
Silvia Martinelli, Alessandro Mazzotta, Mattia Longaroni, et al.
Drug and Alcohol Dependence (2024) Vol. 264, pp. 112424-112424
Open Access | Times Cited: 11
The Potential Role of Mitochondria in the Microbiota-Gut-Brain Axis: Implications for Brain Health
Lei Qiao, Ge Yang, Peng Wang, et al.
Pharmacological Research (2024) Vol. 209, pp. 107434-107434
Open Access | Times Cited: 10
Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways
Iwona Piątkowska‐Chmiel, Katarzyna Wicha-Komsta, Kamil Pawłowski, et al.
Cellular and Molecular Neurobiology (2025) Vol. 45, Iss. 1
Open Access | Times Cited: 1
Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure
Gwangho Yoon, Young‐Kook Kim, Juhyun Song
Pharmacological Research (2019) Vol. 152, pp. 104615-104615
Closed Access | Times Cited: 64
Recent advances in understanding the role of glucagon-like peptide 1
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
F1000Research (2020) Vol. 9, pp. 239-239
Open Access | Times Cited: 52
Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1−42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease
Nazia Siddiqui, Javed Ali, Suhel Parvez, et al.
Neuropharmacology (2021) Vol. 195, pp. 108662-108662
Closed Access | Times Cited: 49
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
Jan Detka, Katarzyna Głombik
Pharmacological Reports (2021) Vol. 73, Iss. 4, pp. 1020-1032
Open Access | Times Cited: 47
Dietary Regulation of Gut-Brain Axis in Alzheimer’s Disease: Importance of Microbiota Metabolites
Dulce M. Frausto, Christopher B. Forsyth, Ali Keshavarzian, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 42
Relationship Between Short-chain Fatty Acids and Parkinson’s Disease: A Review from Pathology to Clinic
Wen-Xiang Duan, Fen Wang, Junyi Liu, et al.
Neuroscience Bulletin (2023) Vol. 40, Iss. 4, pp. 500-516
Open Access | Times Cited: 22
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Li Chen, Jiayi Zhang, Yu Sun, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1973-1984
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top